Ceftazidime–avibactam regimens were independently associated with lower 30-day mortality versus other active antimicrobials in a Brazilian retrospective cohort of patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. The study adds to ongoing efforts to define what works best after carbapenem resistance emerges in bloodstream pathogens. The findings come as the broader evidence base continues to emphasize pathogen-specific, regimen-level decisions in severe Gram-negative infections—where empiric coverage often falls behind rapid resistance evolution.